Humana (HUM) Stock Forecast & Price Target

Humana is supported by a durable niche in government-sponsored coverage, with most medical membership tied to Medicare, Medicaid, and Tricare, while its expanding CenterWell platform adds higher-value care delivery through primary care, home health, and pharmacy services. The excerpts suggest solid operating momentum, including 4.3% y/y CenterWell Home episodic admissions growth in 1Q26 and an adj. EPS beat to $10.31 versus $10.16 consensus, alongside management’s reaffirmation of FY26 adj. EPS “at least” $9 and improving early medical/Rx trends. Despite near-term margin pressure from seasonality, acquisitions, and the 94.5% CenterWell operating cost ratio in 1Q26, the company appears to have enough margin expansion capacity to absorb CY26 volatility and support recovery toward stronger Individual MA margins by CY28.

Humana is viewed negatively because its growth is increasingly exposed to Medicare Advantage utilization pressure, with 25.0% y/y Individual MA growth in CY26 likely to lift lower-margin age-ins, steepen the MLR slope versus CY25, and create a 684 bps spread between 1Q26 and 4Q26E Insurance segment MLR. Regulatory and reimbursement risks remain material, including potential MA benchmark cuts, coding intensity changes, and Medicaid redetermination headwinds, while rising competition could compress margins more than expected. The company’s EPS trajectory also appears heavily dependent on Stars recovery and execution in cost control, network contracting, and HC Services, where the business may fail to reduce medical costs below capitated revenues.